Series C: e-Books on Cancer & Oncology

VOLUME THREE

Cancer Patients’ Resources on Therapies

2020

Editor: Stephen J. Williams, PhD

sjwilliamspa@comcast.net

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Aviva Lev-Ari, PhD, RN

Editor-in-Chief BioMed e-Series of e-Books

Leaders in Pharmaceutical Business Intelligence, Boston

avivalev-ari@alum.berkeley.edu

Other e-Books in the BioMedicine e-Series

 

WE ARE ON AMAZON.COM

https://lnkd.in/ekWGNqA

 

 

Open Access Online Journal

http://www.pharmaceuticalIntelligence.com

is a scientific, medical and business, multi-expert authoring environment for information syndication in several domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.

This e-Book is a comprehensive review of ONCOLOGY PATIENTS RESOURCES including related opportunities for Targeted Therapy written by Experts, Authors, Writers. The results of Original Research are gaining value added for the e-Reader by the Methodology of Curation. The e-Book’s articles have been published on the Open Access Online Scientific Journal, since April 2012.  All new articles on this subject, will continue to be incorporated, as published with periodical updates.

ALL CONTENT BELOW REPRESENTS WORK-IN_PROGRESS

List of Contributors

Author’s Name linked to Author’s Biographies

Series C: e-Books on Cancer & Oncology

Series C Content Consultant: Larry H. Bernstein, MD, FCAP

 

Editor: Stephen J. Williams, PhD

Aviva Lev-Ari, PhD, RN

Content Architecture DRAFT of eTOCs

PART ONE Leading Institutions in Cancer Research and Therapy: The Frontier on Immunotherapy and on Radiation Oncology

Chapter One: National Cancer Institute (NCI), Bethesda, MD

Article ID 1.1.1

Artical ID 1.1.2

Article ID 1.1.3

Artical ID 1.1.4

Article ID 1.1.5

Chapter Two: Cancer Research Institute (CRI), NY

Article ID 1.2.1

Artical ID 1.2.2

Article ID 1.2.3

Artical ID 1.2.4

Article ID 1.2.5

Chapter Three: Dana Farber Cancer Institute, Boston

Article ID 1.3.1

Artical ID 1.3.2

Article ID 1.3.3

Artical ID 1.3.4

Article ID 1.3.5

Chapter Four: Sloan Kettering Cancer Center, NY

Article ID 1.4.1

Artical ID 1.4.2

Article ID 1.4.3

Artical ID 1.4.4

Article ID 1.4.5

Chapter Five: MD Anderson Cancer Center Houston

Article ID 1.5.1

Artical ID 1.5.2

Article ID 1.5.3

Artical ID 1.5.4

Article ID 1.5.5

Chapter Six: Koch Institute for Center for Integrative Cancer Research @MIT

• Developing nanotechnology-based cancer therapeutics
• Creating novel devices for cancer detection and monitoring
• Exploring the molecular and cellular basis of metastasis
• Advancing personalized medicine through analysis of cancer pathways and drug resistance
• Engineering the immune system to fight cancer

Chapter Seven: Technion, Rappaport School of Medicine – Research Labs

http://www.technioncancer.co.il/ResearchGroups.php
http://www.ats.org/site/PageServer?pagename=about_research_cancer
http://www.technioncancer.co.il/lab.php?id=3

http://www.rappaport.org.il/Rappaport/Templates/ShowPage.asp?DBID=1&TMID=610&FID=77&PID=0&IID=1268

PART TWO: Pre-Clinical Research Frontier – Cancer of the GI – Gastric, Carcinoid, GIST and GU: Renal, Bladder, Prostate

Chapter One: Genomics

Article ID 2.1.1 Lung

Artical ID 2.1.2 Breast and Ovarian

Article ID 2.1.3 Stomach, GI and Colonorectal

Artical ID 2.1.4 Liver, Pancreatic and Biliary

Article ID 2.1.5 GU

Artical ID 2.1.6 Heart – Correlation between Cancer and Cardiovascular Diseases

Causes

2.1.6.1 Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/08/reuben-shaw-ph-d-a-geneticist-and-researcher-at-the-salk-institute-metabolism-influences-cancer/

2.1.6.2 Heart Tumors: Etiology and Classification

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/08/heart-tumors-etiology-and-classification/

2.1.6.3  Amyloidosis with Cardiomyopathy

Author: Larry H Bernstein, MD, FACP

http://pharmaceuticalintelligence.com/2013/03/31/amyloidosis-with-cardiomyopathy/

Biomarkrs

2.1.6.4 Stabilizers that prevent Transthyretin-mediated Cardiomyocyte Amyloidotic Toxicity

Larry H. Bernstein, MD, FCAP

http://pharmaceuticalintelligence.com/2013/12/02/stabilizers-that-prevent-transthyretin-mediated-cardiomyocyte-amyloidotic-toxicity/

2.1.6.5  Cancer Symptom Science: On the Mechanisms underlying the Expression of Cancer-related Symptoms

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/15/cancer-symptom-science-on-the-mechanisms-underlying-the-expression-of-cancer-related-symptoms/

Therapies

2.1.6.6 Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

2.1.6.7 Radiation and Chemotherapy Therapy: The Pharmacological Risk for Developing Cardiovascular Disease

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/08/20316/

2.1.6.8 3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

PART TWO: Innovations in Chemo and Radiation Therapy

Chapter Two: 

3.1            New Developments in Cancer Screening

3.1.1         Colorectal CA via stool DNA analysis
3.1.2         HPV screening vs. Pap smear in cervical cancer
3.2            Diagnostic Radiology:Updates in 3 major disease sites:

3.2.1        Melanoma
3.2.2        Pancreatic cancer
3.2.3        Brain CA. new developments in the treatment of glioblastoma..Dr Nir

3.3New Applications and Techniques in Radiation Oncology

3.3.1            Monitoring the effects of treatment with PET/CT
3.3.2            Is there a role for PET/MRI?
3.3.3            SBRT (stereotactic body radiation therapy) for early lung cancer:  will it displace surgery?
3.3.4            Proton beam therapy: Is it coming to your neighborhood soon?

Introduction

FROM: therapies using antibodies targeting specific pathways, such as the epidermal growth factor (EDGF), vascular endothelium growth factor (VEGF), platelet derived growth factor (PDGF) and others that may drive tumor development and progression.

TO: Key subjectsin immunotherapy, http://www.int-imm-foundation.com/

o      The role of GcMAF in macrophage antigen processing and anti-angiogenesis.

o      The role of Treg (suppressor T cells) in the maintenance of tumor remission.

o      Identification of additional factors that affect blastoid transformation.

o      The role of Vitamin D in the regulation of the inflammatory response and cancer response.

o      Identification of additional plasma proteins that effect innate immunity.

o      The role of hyperthermia in augmenting innate and acquired immunity.

o      The role of thermography in the screening and follow-up of cancer patients

• The effect of selected micronutrients in combination with Immunepheresis

Article ID 2.2.1

Artical ID 2.2.2

Article ID 2.2.3

Artical ID 2.2.4

Article ID 2.2.5

Chapter Three: Cancer Imaging for Diagnosis

Article ID 2.3.1

Artical ID 2.3.2

Article ID 2.3.3

Artical ID 2.3.4

Article ID 2.3.5

Chapter Four: Chemo-Therapy and Radiation Therapy

Article ID 2.4.1

Artical ID 2.4.2

Article ID 2.4.3

Artical ID 2.4.4

Article ID 2.4.5

Chapter Five: Surgery and Modalities of Tumor Reduction

Article ID 2.5.1

Artical ID 2.5.2

Article ID 2.5.3

Artical ID 2.5.4

Article ID 2.5.5

PART THREE:  Brain Cancer: Gliomas, Spinal Cancer, Schwannomas, Eye Cancer & Retinoblastoma,

 Chapter One

Article ID 3.1.1

Artical ID 3.1.2

Article ID 3.1.3

Artical ID 3.1.4

Article ID 3.1.5

Chapter Two

Article ID 3.2.1

Artical ID 3.2.2

Article ID 3.2.3

Artical ID 3.2.4

Article ID 3.2.5

Chapter Three

Article ID 3.3.1

Artical ID 3.3.2

Article ID 3.3.3

Artical ID 3.3.4

Article ID 3.3.5

Chapter Four

Article ID 3.4.1

Artical ID 3.4.2

Article ID 3.4.3

Artical ID 3.4.4

Article ID 3.4.5

Chapter Five

Article ID 3.5.1

Artical ID 3.5.2

Article ID 3.5.3

Artical ID 3.5.4

Article ID 3.5.5

PART FOUR:  Skin Cancer

Chapter One

Article ID 4.1.1

Article ID 4.1.2

Article ID 4.1.3

Article ID 4.1.4

Article ID 4.1.5

Chapter Two

Article ID 4.2.1

Article ID 4.2.2

Article ID 4.2.3

Article ID 4.2.4

Article ID 4.2.5

Chapter Three

Article ID 4.3.1

Article ID 4.3.2

Article ID 4.3.3

Article ID 4.3.4

Article ID 4.3.5

Chapter Four

Article ID 4.4.1

Article ID 4.4.2

Article ID 4.4.3

Article ID 4.4.4

Article ID 4.4.5

Chapter Five

Article ID 4.5.1

Article ID 4.5.2

Article ID 4.5.3

Article ID 4.5.4

Article ID 4.5.5

PART FIVE:  Thymoleukemoid: Lymphomas, Leukemias, Thymus

Chapter One

Article ID 5.1.1

Article ID 5.1.2

Article ID 5.1.3

Article ID 5.1.4

Article ID 5.1.5

Chapter Two

Article ID 5.2.1

Article ID 5.2.2

Article ID 5.2.3

Article ID 5.2.4

Article ID 5.2.5

Chapter Three

Article ID 5.3.1

Article ID 5.3.2

Article ID 5.3.3

Article ID 5.3.4

Article ID 5.3.5

Chapter Four

Article ID 5.4.1

Article ID 5.4.2

Article ID 5.4.3

Article ID 5.4.4

Article ID 5.4.5

Chapter Five

Article ID 5.5.1

Article ID 5.5.2

Article ID 5.5.3

Article ID 5.5.4

Article ID 5.5.5

PART SIX: Bone Cancer – Osteosarcoma, Chondrosarcoma. Giant Cell Tumors, Ewing Sarcoma, Parosteal Sarcoma, 

Chapter One

Article ID 6.1.1

Article ID 6.1.2

Article ID 6.1.3

Article ID 6.1.4

Article ID 6.1.4

Chapter Two

Article ID 6.2.1

Article ID 6.2.2

Article ID 6.2.3

Article ID 6.2.4

Article ID 6.2.5

Chapter Three

Article ID 6.3.1

Article ID 6.3.2

Article ID 6.3.3

Article ID 6.3.4

Article ID 6.3.5

Chapter Four

Article ID 6.4.1

Article ID 6.4.2

Article ID 6.4.3

Article ID 6.4.4

Article ID 6.4.5

Chapter Five

Article ID 6.5.1

Article ID 6.5.2

Article ID 6.5.3

Article ID 6.5.4

Article ID 6.5.5

PART SEVEN:  Head and Neck: Salivary, Nasopharyngeal

Chapter One

Article ID 7.1.1

Article ID 7.1.2

Article ID 7.1.3

Article ID 7.1.4

Article ID 7.1.5

Chapter Two

Article ID 7.2.1

Article ID 7.2.2

Article ID 7.2.3

Article ID 7.2.4

Article ID 7.2.5

Chapter Three

Article ID 7.3.1

Article ID 7.3.2

Article ID 7.3.3

Article ID 7.3.4

Article ID 7.3.5

Chapter Four

Article ID 7.4.1

Article ID 7.4.2

Article ID 7.4.3

Article ID 7.4.4

Article ID 7.4.5

Chapter Five

Article ID 7.5.1

Article ID 7.5.2

Article ID 7.5.3

Article ID 7.5.4

Article ID 7.5.5

PART EIGHT: Endocrine Cancer: Adrenal, Thyroid, Pituitary; Ovary, Testes.

PART NINE: Soft Tissue Sarcomas (Rhabdomyosarcoma, Fibrosarcoma, Liposarcoma)